CLASS II ONGOING Drug recall · Reported 16 Jul 2025 · FDA Enforcement Report

Duloxetine Delayed-Release Capsules, USP, 40mg recalled

Breckenridge Pharmaceutical is recalling Duloxetine Delayed-Release Capsules, USP, 40mg, distributed nationwide in the US. The recall was initiated on 30 Jun 2025 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot # 230199, Exp. Date 01/31/2026
NDC51991-746, 51991-747, 51991-748, 51991-750
Quantity recalled12,242 30-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0511-2025
FDA event ID
97179
Recalling firm
Breckenridge Pharmaceutical, Berkeley Heights, NJ
Manufacturer
Breckenridge Pharmaceutical, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
30 Jun 2025
FDA classified
9 Jul 2025
Reported
16 Jul 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity
Drug class
Antidepressants

Timeline

30 Jun 2025Recall initiated by company
9 Jul 2025Classified by FDA+9 days
16 Jul 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

Where it was distributed

U.S. Nationwide

Nationwide

Questions about this recall

Why was it recalled?

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Which lots are affected?

Lot # 230199, Exp. Date 01/31/2026

Where was it sold?

U.S. Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Breckenridge Pharmaceutical

All 35

Other Duloxetine recalls

All 57